Medkart backs India’s new price cap on 137 cancer drugs

Medkart says the government’s 30% trade-margin cap on 137 anti-cancer medicines could cut prices by as much as 70% starting November 9. The pharmacy chain is urging patients to verify revised prices and use comparison tools before refilling cancer prescriptions.

Why it matters: - The government’s cap on trade margins for 137 anti-cancer medicines is meant to lower out-of-pocket costs for cancer patients. - The change could save patients around ₹2,500 crore a year, according to the government. - The move affects medicines used in immunotherapy and in treatments for breast, prostate, colon, ovarian and cervical cancers.

What happened: - Medkart welcomed the National Pharmaceutical Pricing Authority’s decision to cap trade margins at 30% on 137 selected non-scheduled anti-cancer medicines. - The cap took effect on November 9. - Medkart urged patients and caregivers to check revised prices before their next refill. - The NPPA announced the change on October 17 under the Department of Pharmaceuticals. - Manufacturers have been directed to publish revised prices. - Retailers and hospitals must charge the updated rates and display revised price lists from November 9.

The details: - Prices of the covered medicines are expected to fall by up to 70%, though the exact reduction will vary by medicine and formulation. - The policy builds on the NPPA’s 2019 intervention on 42 anti-cancer medicines. - The cap applies only to the 137 identified medicines, not to every cancer drug. - Patients can check revised prices on the NPPA website and the Pharma Sahi Daam app. - Medkart said its app and website let patients upload prescriptions, compare generic options and arrange home delivery. - Medkart’s comparison page lets patients search a branded medicine and compare it with a generic equivalent. - The company says patients can also search by medicine name to get a recommended “smart choice” generic alternative, often available for up to 80% less. - Medkart pharmacists are trained to guide patients through those options. - Medkart stocks oncology medicines and has updated its pricing to reflect the revised MRPs effective November 9.

Between the lines: - The pricing move may help only if patients and pharmacies actually switch to the revised rates, so visibility at the counter matters. - Medkart is positioning its comparison tools as a way to help patients navigate a system where the same treatment can still vary widely in cost. - The company’s message is aimed at preserving treatment continuity while pushing patients toward lower-cost generic alternatives when appropriate.

What patients should know: - Patients should confirm whether their prescribed cancer medicine is on the NPPA list. - Patients should not stop or switch cancer medicines without consulting the treating oncologist. - Revised price lists should be visible at pharmacies and hospitals. - Medkart says patients can use its comparison page or search by medicine name to review options.

The bottom line: - The new cap could ease a major cost burden for cancer families, but the savings depend on patients, retailers and hospitals following the revised pricing rules.